Beam Therapeutics Inc. (BEAM) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $1.03M; Additional Paid in CapitalUSD $2.93B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-2.19M; Retained Earnings (Accumulated Deficit)USD $-1.86B.
- 2026-03-31: Common Stock, Value, IssuedUSD $1.03M; Additional Paid in CapitalUSD $2.90B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-1.07M; Retained Earnings (Accumulated Deficit)USD $-1.74B.
- 2025-12-31: Common Stock, Value, IssuedUSD $1.02M; Additional Paid in CapitalUSD $2.88B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $1.11M; Retained Earnings (Accumulated Deficit)USD $-1.64B.
- 2025-09-30: Common Stock, Value, IssuedUSD $1.01M; Additional Paid in CapitalUSD $2.86B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $790.00K; Retained Earnings (Accumulated Deficit)USD $-1.89B.
Beam Therapeutics Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock USD | APIC, Share-based Payment Arrangement, Recognition and Exercise USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.03M | $2.93B | $-2.19M | $-1.86B | $1.07B | 3 month · $19.28M | (m) | (m) |
| 2026-03-31 | $1.03M | $2.90B | $-1.07M | $-1.74B | $1.16B | 3 month · $19.04M | (m) | (m) |
| 2025-12-31 | $1.02M | $2.88B | $1.11M | $-1.64B | $1.24B | 12 month · $94.24M | (m) | (m) |
| 2025-09-30 | $1.01M | $2.86B | $790.00K | $-1.89B | $966.00M | 3 month · $22.75M | (m) | (m) |
| 2025-06-30 | $1.01M | $2.82B | $10.00K | $-1.78B | $1.05B | 3 month · $24.37M | (m) | (m) |
| 2025-03-31 | $1.01M | $2.80B | $160.00K | $-1.68B | $1.13B | 3 month · $26.68M | (m) | (m) |
| 2024-12-31 | $836.00K | $2.30B | $679.00K | $-1.57B | $733.54M | 12 month · $120.66M | (m) | (m) |
| 2024-09-30 | $826.00K | $2.27B | $1.76M | $-1.48B | $791.32M | 3 month · $29.56M | (m) | (m) |
| 2024-06-30 | $824.00K | $2.23B | $-1.11M | $-1.38B | $854.09M | 3 month · $31.60M | (m) | (m) |
| 2024-03-31 | $823.00K | $2.20B | $-921.00K | $-1.29B | $913.49M | 3 month · $29.28M | (m) | (m) |
| 2023-12-31 | $816.00K | $2.17B | $604.00K | $-1.19B | $981.33M | 12 month · $98.65M | (m) | (m) |
| 2023-09-30 | $794.00K | $2.11B | $-2.02M | $-1.33B | $778.94M | 3 month · $25.84M | (m) | (m) |
| 2023-06-30 | $780.00K | $2.05B | $-2.02M | $-1.24B | $811.64M | 3 month · $26.28M | (m) | (m) |
| 2023-03-31 | $744.00K | $1.92B | $-765.00K | $-1.15B | $761.51M | 3 month · $23.92M | (m) | (m) |
| 2022-12-31 | $712.00K | $1.79B | $-2.43M | $-1.06B | $733.47M | 12 month · $84.32M | (m) | (m) |
| 2022-09-30 | $705.00K | $1.74B | $-4.67M | $-1.02B | $714.48M | 3 month · $22.21M | (m) | (m) |
| 2022-06-30 | $703.00K | $1.71B | $-4.19M | $-909.44M | $800.16M | 3 month · $21.58M | (m) | (m) |
| 2022-03-31 | $698.00K | $1.67B | $-2.71M | $-837.49M | $829.07M | 3 month · $18.04M | (m) | (m) |
| 2021-12-31 | $684.00K | $1.59B | $-50.00K | $-768.27M | $826.74M | 12 month · $43.57M | (m) | (m) |
| 2021-09-30 | $677.00K | $1.56B | $19.00K | $-703.57M | $853.81M | 3 month · $12.97M | (m) | (m) |
| 2021-06-30 | $645.00K | $1.22B | $31.00K | $-675.45M | $548.55M | 3 month · $10.45M | (m) | (m) |
| 2021-03-31 | $617.00K | $1.02B | $-24.00K | $-599.20M | $422.43M | 3 month · $4.65M | (m) | 3 month · $4.65M |
| 2020-12-31 | $573.00K | $642.63M | $-9.00K | $-397.64M | $245.56M | 12 month · $15.38M | 12 month · $1.28M | 12 month · $15.38M |
| 2020-09-30 | $504.00K | $501.70M | $41.00K | $-302.17M | $200.07M | 3 month · $3.01M | (m) | 3 month · $3.01M |
| 2020-06-30 | $496.00K | $497.87M | $173.00K | $-267.72M | $230.82M | 3 month · $2.77M | (m) | 3 month · $2.77M |
| 2020-03-31 | $491.00K | $494.75M | $-344.00K | $-233.50M | $261.39M | 3 month · $2.79M | 3 month · $1.28M | 3 month · $2.79M |
| 2019-12-31 | $73.00K | $1.85M | $16.00K | $-203.04M | $-201.10M | 12 month · $7.03M | 12 month · $12.71M | 12 month · $7.03M |
| 2019-09-30 | (m) | (m) | (m) | (m) | $-172.06M | (m) | (m) | 3 month · $2.03M |
| 2019-06-30 | (m) | (m) | (m) | (m) | $-151.87M | (m) | (m) | 3 month · $2.07M |
| 2019-03-31 | (m) | (m) | (m) | (m) | $-132.99M | (m) | (m) | 3 month · $869.00K |
| 2018-12-31 | (m) | (m) | (m) | (m) | $-117.41M | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |